HBIO
Income statement / Annual
Last year (2024), Harvard Bioscience, Inc.'s total revenue was $94.14 M,
a decrease of 16.14% from the previous year.
In 2024, Harvard Bioscience, Inc.'s net income was -$12.41 M.
See Harvard Bioscience, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$94.14 M |
$112.25 M |
$113.34 M |
$118.90 M |
$102.10 M |
$116.18 M |
$120.77 M |
$101.88 M |
$104.52 M |
$108.66 M |
| Cost of Revenue |
$39.37 M
|
$46.18 M
|
$52.52 M
|
$51.25 M
|
$44.06 M
|
$51.85 M
|
$57.59 M
|
$54.29 M
|
$56.11 M
|
$59.94 M
|
| Gross Profit |
$54.77 M
|
$66.07 M
|
$60.82 M
|
$67.65 M
|
$58.04 M
|
$64.32 M
|
$63.18 M
|
$47.60 M
|
$48.42 M
|
$48.72 M
|
| Gross Profit Ratio |
0.58
|
0.59
|
0.54
|
0.57
|
0.57
|
0.55
|
0.52
|
0.47
|
0.46
|
0.45
|
| Research and Development Expenses |
$10.41 M
|
$11.76 M
|
$12.33 M
|
$10.80 M
|
$8.69 M
|
$10.72 M
|
$10.99 M
|
$5.65 M
|
$5.39 M
|
$6.42 M
|
| General & Administrative Expenses |
$21.49 M
|
$22.78 M
|
$24.49 M
|
$24.31 M
|
$23.51 M
|
$22.76 M
|
$21.38 M
|
$18.58 M
|
$20.95 M
|
$19.83 M
|
| Selling & Marketing Expenses |
$22.21 M
|
$24.11 M
|
$25.04 M
|
$24.64 M
|
$19.92 M
|
$23.26 M
|
$24.44 M
|
$21.04 M
|
$20.49 M
|
$20.58 M
|
| Selling, General & Administrative Expenses |
$43.71 M
|
$46.89 M
|
$49.53 M
|
$48.95 M
|
$43.43 M
|
$46.02 M
|
$45.83 M
|
$39.61 M
|
$41.44 M
|
$40.41 M
|
| Other Expenses |
$0.00
|
$5.53 M
|
$6.12 M
|
$5.84 M
|
$5.71 M
|
$5.75 M
|
-$4.28 M
|
-$740,000.00
|
-$179,000.00
|
-$1.26 M
|
| Operating Expenses |
$54.11 M
|
$64.18 M
|
$67.99 M
|
$65.59 M
|
$57.82 M
|
$62.49 M
|
$62.20 M
|
$47.70 M
|
$49.55 M
|
$49.65 M
|
| Cost And Expenses |
$93.48 M
|
$110.36 M
|
$120.50 M
|
$116.84 M
|
$101.88 M
|
$114.34 M
|
$119.79 M
|
$101.98 M
|
$105.66 M
|
$109.59 M
|
| Interest Income |
$0.00
|
$0.00
|
$2.55 M
|
$1.54 M
|
$4.83 M
|
$5.41 M
|
$0.00
|
$0.00
|
$3,000.00
|
$8,000.00
|
| Interest Expense |
-$3.21 M
|
$3.59 M
|
$2.25 M
|
$1.54 M
|
$4.83 M
|
$5.41 M
|
$5.37 M
|
$713,000.00
|
$642,000.00
|
$854,000.00
|
| Depreciation & Amortization |
$0.00
|
$7.00 M
|
$7.58 M
|
$7.62 M
|
$7.63 M
|
$7.73 M
|
$7.84 M
|
$2.91 M
|
$4.27 M
|
$2.82 M
|
| EBITDA |
-$6.21 M |
$8.03 M |
$944,000.00 |
$11.31 M |
$5.49 M |
$7.50 M |
$5.36 M |
-$101,000.00 |
$1.80 M |
$1.73 M |
| EBITDA Ratio |
-0.07
|
0.07
|
-0.01
|
0.06
|
0.05
|
0.06
|
0.02
|
0.02
|
0.01
|
0.01
|
| Operating Income Ratio |
-0.07
|
0.02
|
-0.06
|
0.01
|
-0.01
|
0.01
|
0.01
|
-0
|
-0.03
|
-0.02
|
| Total Other Income/Expenses Net |
-$5.45 M
|
-$4.45 M
|
-$2.25 M
|
-$2.21 M
|
-$7.51 M
|
-$5.88 M
|
-$8.96 M
|
-$1.99 M
|
-$81,000.00
|
-$1.90 M
|
| Income Before Tax |
-$11.67 M
|
-$2.56 M
|
-$9.18 M
|
-$140,000.00
|
-$7.29 M
|
-$5.50 M
|
-$8.52 M
|
-$2.09 M
|
-$3.08 M
|
-$3.61 M
|
| Income Before Tax Ratio |
-0.12
|
-0.02
|
-0.08
|
-0
|
-0.07
|
-0.05
|
-0.07
|
-0.02
|
-0.03
|
-0.03
|
| Income Tax Expense |
$740,000.00
|
$859,000.00
|
$337,000.00
|
$148,000.00
|
$518,000.00
|
-$815,000.00
|
-$3.68 M
|
-$1.22 M
|
$1.23 M
|
$15.43 M
|
| Net Income |
-$12.41 M
|
-$3.42 M
|
-$9.52 M
|
-$288,000.00
|
-$7.81 M
|
-$4.69 M
|
-$3.46 M
|
-$865,000.00
|
-$4.31 M
|
-$19.04 M
|
| Net Income Ratio |
-0.13
|
-0.03
|
-0.08
|
-0
|
-0.08
|
-0.04
|
-0.03
|
-0.01
|
-0.04
|
-0.18
|
| EPS |
-0.28 |
-0.0805 |
-0.23 |
-0.0071 |
-0.2 |
-0.12 |
-0.0966 |
-0.0257 |
-0.13 |
-0.57 |
| EPS Diluted |
-0.28 |
-0.0805 |
-0.23 |
-0.0071 |
-0.2 |
-0.12 |
-0.095 |
-0.0249 |
-0.13 |
-0.57 |
| Weighted Average Shares Out |
$43.54 M
|
$42.42 M
|
$41.41 M
|
$40.34 M
|
$38.64 M
|
$37.81 M
|
$35.83 M
|
$33.60 M
|
$34.21 M
|
$33.59 M
|
| Weighted Average Shares Out Diluted |
$43.54 M
|
$42.42 M
|
$41.41 M
|
$40.34 M
|
$38.64 M
|
$37.81 M
|
$36.45 M
|
$34.75 M
|
$34.21 M
|
$33.59 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
